Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease associated with degeneration of motor neurons in the spinal cord and motor cortex. Frontotemporal lobar degeneration with ubiquitin inclusions (FTLD-U) is a form of dementia resulting from neuronal loss in the frontal and temporal lobes of the brain (1) . Despite clear clinico-pathological differences, these disorders share a high degree of co-morbidity and may represent a spectrum of related disorders (2) . Although the underlying pathological process in these diseases is not clear, the identification of the heterogeneous ribonucleoprotein (hnRNP), transactivation response DNA-binding protein-43 (TDP-43) as a major protein component of ubiquitinated inclusions in ALS and FTLD-U patients has focused research on the role of hnRNP accumulation in these in these diseases (3) .
TDP-43 is a predominantly nuclear protein, although it can shuttle between the nucleus and cytosol. The protein has roles in RNA processing, including transcription, pre-mRNA splicing, transport and stabilization of mRNA (4, 5) . In ALS and FTLD-U post-mortem CNS tissues, TDP-43 accumulates predominantly as a C-terminal fragment of 25 or 35 kDa in cytosolic inclusions. The aggregated TDP-43 is also heavily ubiquitinated, and phosphorylated at the C-terminus (6) . A key role for abnormal TDP-43 homeostasis in TDP-43 proteinopathies (ALS and FTLD-U) has been supported by the identification of more than 40 mutations to date in the TDP-43 gene (TARDBP) linked to disease (7) .
Although cell studies have elegantly demonstrated that accumulation of C-terminal TDP-43 in the cytosol of neurons results in detrimental outcomes, potentially related to both loss of function and toxic gain of function, there is still a very poor understanding of the processes leading to TDP-43 accumulation and its role in disease progression of ALS and FTLD-U. A key role for TDP-43 localization to cytosolic stress granules (SGs) has been identified (7, 8) . Cytosolic RNA SGs are sites of stalled mRNA pre-initiation complexes and are formed by cells during certain stresses to allow cellular resources to be directed to upregulation of stress-related proteins (7) . Upon removal of stress, SGs rapidly disperse to allow normal 4 mRNA processing to return. TDP-43, together with many additional hnRNPs localize to SGs in many cell types, including neurons during cell stress. Whether this is a preliminary step in TDP-43 cytosolic aggregation is unclear (7), however, TDP-43 has been shown to bind to various SG proteins both in cells and in post-mortem tissue from ALS and FTLD-U patients (9) . Further support for the role of TDP-43 localization to SGs being an important aspect of disease progression comes from studies identifying additional hnRNPs including fused in sarcoma (FUS, also known as hnRNP P2), hnRNP A1 and hnRNP A3 in both SGs and cytosolic inclusions in ALS (10) (11) (12) (13) . TDP-43 accumulation in SGs can lead to subsequent abnormal protein aggregation (14) .
The potential role for TDP-43 SG localization as a key step in ALS and FTLD-U neuropathology has led to major efforts to understand the mechanisms controlling TDP-43 accumulation in SGs. The movement of hnRNPs between the nucleus, cytosol and SGs is controlled by various signaling kinases including extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38. It has been shown that p38 controls stress-related accumulation of hnRNP A1 (15) . JNK controls cytosolic movement of hnRNP K via phosphorylation of serine residues (16) and we have shown that JNK specifically controls TDP-43, but not HuR, localization to SGs in cells exposed to the mitochondrial inhibitor, paraquat (17) . This was supported by Higashi et al who demonstrated that another mitochondrial toxin (sodium arsenite) also induced JNK-mediated TDP-43 phosphorylation and accumulation into SGs (18) . Moreover, Suzuki et al reported that JNK was involved in TDP-43-mediated cell death (19) . Other kinases also potentially control TDP-43 accumulation. Ayala et al have shown that ERK can co-localize with TDP-43 during cell stress (20) . It was recently reported that AMP-activated kinase alpha 1 (AMPK1) can control TDP-43 accumulation in vitro, while activated AMPK1 was associated with mislocalized TDP-43 in ALS patients (21) . CDC7, a kinase involved in control of the cell cycle also co-localizes with phosphorylated TDP-43 in FTLD patients (22) . To expand our understanding of how kinases control TDP-43 accumulation in SGs we recently screened a large number of kinase inhibitors for their ability to modulate TDP-43 SG localization in neuronal cultures. We demonstrated that in addition to JNK, inhibitors of cyclin-dependent kinases (CDKs) provided robust abrogation of TDP-43 accumulation in SGs. Moreover, these inhibitors were able to reverse 5 accumulation of pre-formed TDP-43-positive SGs (23) . We also observed that CDK inhibitors blocked aggregation of C-terminal TDP-43 in cells transfected with a C-terminal fragment of TDP-43, providing strong support for CDK control of disease-relevant TDP-43 accumulation. However, the mechanism by which CDKs control TDP-43 cytosolic accumulation during stress is not clear. Delineating this process is essential to understanding the early stages TDP-43 accumulation in disease and offering potential targets to block accumulation at its earliest stage.
In this study we found that selective inhibitors of CDK2 abrogated the cytosolic accumulation of TDP-43. We have reported recently that inhibitors of CDKs can prevent and reverse formation of TDP-43-positive stress granules including endogenous TDP-43 and cells transfected with C-terminal constructs (23) . The mechanism controlling this is unclear as TDP-43 does not contain classical CDK phosphorylation consensus sites in its primary sequence. However, we found in our previous study that CDK (and additional kinase) inhibitors induced almost identical changes to both TDP-43 and hnRNP K when added to paraquat-treated cells (23) . hnRNP K does have consensus sites for CDK2; S/T-P-x-K/R (i.e., residues Ser216, Pro217 and Ser284, Pro285) both of which are known to be phosphorylated in cells (16, (26) (27) (28) supporting the possibility that interaction between TDP-43 and hnRNP K may be an important factor in controlling TDP-43 accumulation. To examine this further we initially determined whether TDP-43 and hnRNP K consistently co-accumulate in the cytosol during cell stress.
SH-SY5Y cells treated with 1 mM paraquat overnight revealed a high level of co-occurrence of TDP-43 and hnRNP K in SGs as assessed using immunofluorescence analysis (Figures 1 and 2A) . We observed that 89  12 % of hnRNP K-positive SGs were also positive for TDP-43. In contrast, 63  8% of HuR-positive SGs were positive for TDP-43 demonstrating a significantly lower level of concordance between HuR and TDP-43 compared to hnRNP K and TDP-43 (p<0.01) as previously reported (23) . To determine if the colocalization of hnRNP K and TDP-43 was consistent in other cell models, we examined NSC34 motor neuron hybrid cells stably transfected with mCherry-tagged full length human TDP-43. As paraquat did not induce robust SGs in this cell-type (data not shown), we treated the cells with 300 M sodium arsenite for 3 hr. mCherry vector alone showed diffuse localization throughout the cell and this was largely unchanged upon treatment with sodium arsenite. In mCherry-TDP-43 expressing cells, without treatment, some accumulation of TDP-43 was occasionally observed in the perinuclear region of transfected cells (Supp. Figure 1, white arrows) . Interestingly, TDP-43 accumulation was greater than hnRNP K, perhaps associated with a higher propensity to aggregate as we have demonstrated previously (14) . No accumulation of hnRNP K was observed with this treatment in vector control cells, demonstrating that the presence of the human TDP-43 expression enhanced the cytosolic hnRNP K accumulation during stress.
Primary murine cortical neurons were also treated with sodium arsenite for 3 hr and again, co-localization of TDP-43 and hnRNP K was observed in the cytosol of treated cells (Supp. Figure 2) . These findings clearly demonstrate that TDP-43 and hnRNP K co-localize in the cytosol in different cell types and during different stresses and this is consistent with an important association between these proteins. 
Phosphorylated CDK2 co-localizes with TDP-43 and hnRNP K in stress granules.
Although some of the inhibitors used, particularly roscovitine and CDK2 Inhibitor I, have a selective inhibitory action on CDK2 over CDK1 and CDK5, it remained a possibility that the inhibitory activity was via modulation of alternative CDKs. Therefore, we investigated whether CDK2 co-localizes with TDP-43 and hnRNP K in SGs as co-localization would be expected if CDK2 modulates SG localization of these hnRNPs. In fact, we observed strong co-localization of total and, importantly, phosphorylated (active) CDK2 with TDP-43 and hnRNP K in SGs ( Figure 2B Interestingly, analysis of total p-CDK2 levels in paraquat-treated cells did not reveal a substantial change in detectable levels (Supp Figure 3) . Induction of cell stress was confirmed by elevated levels of phosphorylated p38, a known stress-responsive kinase (Supp Figure 3) . The lack of a substantial change in 9 phosphorylated CDK2 levels during stress could either indicate that the changes are highly localized and not easily determined in cell extracts, or that constitutively phosphorylated CDK2 localizes with hnRNP K and TDP-43 in SGs during stress.
CDK2 inhibitors block hnRNP K phosphorylation and hnRNP K and TDP-43 accumulation in stress granules.
From these studies, we theorized that CDK2 may control localization of hnRNP K and associated TDP-43 to SGs through phosphorylation of the hnRNP K consensus sites for CDK2 (e.g., residues Ser216 and/or Ser284). In support of this, we observed SG co-localization of phosphorylated hnRNP K (using antisera to p-hnRNP K Ser284 or p-hnRNP K Ser216) with TDP-43 (Figures 2D and E and 5A) and CDK2 ( Figure 2F ).
Two out of three CDK2 inhibitors tested reduced total cellular levels of phosphorylated hnRNP K ( Figure   5B ) and blocked accumulation of phosphorylated (and total) hnRNP K and TDP-43 in SGs ( Figure 2A , D and E and Figure 5A ). Olomoucine had limited effect on total CDK2 phosphorylation in cell lysates ( Figure   5B ) but still inhibited hnRNP K localization to SGs ( Figure 5A ). This may reflect action on cytosolic CDK2 that cant be detected in total cell lysates or could involve inhibition of alternative CDKs which we haven"t yet been able to determine. CDK2 inhibition also abrogated co-localization of total CDK2 and p-hnRNP K ( Figure 2F ). Similar effects were not observed for CDK5. This provided strong support for a mechanism involving CDK2 phosphorylation of hnRNP K in controlling co-localization of both hnRNP K and TDP-43 to SGs.
Mutation of hnRNP K phosphorylation sites (Ser216 and Ser284) inhibits hnRNP K and TDP-43 colocalization to stress granules.
To provide further support that phosphorylation of key residues on hnRNP K is essential for controlling TDP-43 localization to SGs, we generated phosphorylation site mutant hnRNP Ks containing Ser284Ala and Ser216Ala/Ser284Ala and transfected HEK293 cells with the GFP-tagged constructs (compared to cells transfected with wild-type (WT) hnRNP K-GFP. As shown in Figure 3D , compared to WT hnRNP K-GFP, both mutant forms of hnRNP K revealed reduced capacity to bind TDP-43 in co-immunoprecipitation Figure 4B ). This effect was substantially stronger in the Ser216Ala/Ser284Ala-hnRNP K-GFP transfected cells (Figure 6 and Supp. Figure 4C ). As expected, additional TDP-43-positive stress granules that likely formed with endogenous hnRNP K were still evident in mutant hnRNP K-transfected cells. However, these results do provide further evidence that phosphorylation of specific serine residues on hnRNP K has a key role in modulating hnRNP K and also TDP-43 localization to SGs.
Depletion of hnRNP K inhibits formation of TDP-43 stress granules.
If hnRNP K is essential for controlling TDP-43 localization to SGs, then its depletion should inhibit TDP-43 SG accumulation. We investigated this by using siRNA against hnRNP K to deplete levels of the protein in SH-SY5Y cells. siRNA against hnRNP K significantly depleted levels of hnRNP K in treated cells ( Figure   7A ), while control siRNA had no effect. Knockdown of hnRNP K did not alter the level of cell viability under basal and paraquat-treated conditions demonstrating that the loss of hnRNP K was not toxic to the cells (Supp. Figure 5 ). siRNA treatment prevented formation of hnRNP K-positive SGs as expected.
Likewise, rarely were TDP-43-positive SG observed in siRNA treated cells after paraquat exposure ( Figure   7B and C). In fact, there was also an analogous loss of HuR SGs ( Figure 7B ). This contrasted with our finding above that inhibition of hnRNP K phosphorylation reduced formation of TDP-43 positive SGs but not SGs per se (i.e. HuR positive). This suggests that while phosphorylated hnRNP K may be associated with TDP-43 SG accumulation, the hnRNP K protein may have additional roles in controlling SG dynamics. Our findings however, demonstrated that hnRNP K expression was required for robust SG formation in response to paraquat and is consistent with the need for hnRNP K to control TDP-43 accumulation in SGs.
Loss of CDK2 and hnRNP K expression in motor neurons is a feature of ALS.
To examine whether there was a similar relationship between hnRNP K and TDP-43 ex vivo, we examined cervical spinal cord motor neurons in control and ALS cases for expression of hnRNP K. We observed a robust decrease in total cellular hnRNP K levels in motor neurons of both SALS (sporadic) and FALS (familial, with unknown mutations) cases of ALS. This decrease was indicative of a parallel decrease in both cytosolic and nuclear hnRNP K in these cells ( Figure 8A-F) . No hnRNP K-positive cytosolic inclusions were observed. To determine if these changes were associated with altered CDK2 activity, we also examined the same tissues for total CDK2 expression (antisera to phospho-CDK2 did not produce a robust signal on the tissue sections). We observed that nuclear, cytosolic and total CDK2 levels were decreased in the SALS and FALS tissues in a pattern very similar to the decrease in hnRNP K ( Figure 8G-I ). To ensure that these changes were not associated with general protein loss, we compared the staining to neurofilament H (NF H) in the same tissues and found that the NF H was not significantly altered ( Figure 8 ). These findings demonstrate that CDK2 and hnRNP K expression are substantially lower in spinal cord motor neurons of ALS cases.
Discussion
The loss of nuclear TDP-43 and accumulation and ultimately aggregation of C-terminal TDP-43 fragments in the cytosol is believed to be an important phenomenon contributing to the pathophysiology of ALS and FTLD-U. However, the precise molecular pathways controlling this process are not well understood. TDP-43 is an hnRNP and co-localizes with additional hnRNPs in cytosolic SGs, where it may subsequently progress to larger insoluble aggregates. The mechanism controlling early TDP-43 accumulation in SGs are being investigated. Our recent studies have identified a key role for specific kinases controlling cytosolic accumulation of TDP-43 (23) . We have demonstrated that JNK, CDKs and GSK3 are likely to have important roles in the formation and/or maintenance of TDP-43 positive SGs (14, 17, 23) . This has been 12 supported by subsequent reports describing a role for JNK controlling SG accumulation of C-terminal TDP-43 and TDP-43 toxicity (18, 19) and the presence of kinases associated with TDP-43 aggregates in ALS or FTLD-U patients (20, 22) .
While these studies clearly demonstrate a key role for kinases in modulating TDP-43 accumulation, it is not clear how this is mediated at the molecular level. TDP-43 does not contain known phosphorylation consensus sites for CDKs (or JNK) (29) . While it remains a possibility that TDP-43 could be phosphorylated via non-classical sites, it is perhaps more likely that TDP-43 movement is controlled through interaction with additional SG proteins. We report here evidence that TDP-43 consistently co-localizes with hnRNP K in cytosolic SGs in a range of cell types and with different stress inducers. We also confirm that TDP-43 and hnRNP K appear to interact directly or indirectly in the cytosol. This is consistent with previous reports indicating a direct association between these proteins as determined by proteomic analysis (30) . Moreover, we have shown that expression of hnRNP K is substantially diminished in spinal cord motor neurons in ALS cases, along with CDK2. This is associated with a loss throughout the cell and is not restricted to nucleus or cytosol ( Figure 8 ). Whether there is a relationship between changes to hnRNP K and TDP-43 remains to be determined and will require assessment of levels in the same cells of serial sections using co-localization immunohistochemistry. Our findings are however, the first to describe a prominent change to hnRNP K in ALS spinal cord tissue. The reason this has not been reported previously is again likely to represent past examination of cells specifically expressing cytoplasmic inclusions of TDP-43 (31), rather than examination of cytosolic and nuclear hnRNP K in all cells with a motor neuron-like morphology as we have done here.
We also observed that ~12% of cells contained cytosolic TDP-43-positive inclusions in sections from the same tissue samples, although we did not identify any hnRNP K-positive inclusions in the ALS tissues (hnRNP K may be lost from these inclusions at an early stage as we propose in Figure 9 and have reported for HuR in vitro previously). However, our analysis of hnRNP K expression was done on all cells, not just those potentially containing TDP-43 inclusions. A global reduction to hnRNP K is clearly a prominent feature across the ALS tissue. The consequences in vivo of a robust loss of hnRNP K remain to be determined but could have important consequences for RNA processing. Whether hnRNP K has a significant role in TDP-43 proteinopathies is not known. The protein has key roles in chromatin remodeling, transcription, splicing and translation processes (33) and abnormal metabolism has been associated with several disorders including cancers and the neurodegenerative disorder, spinocerebellar ataxia type 10 (34-37). In the latter, changes to hnRNP K metabolism appear to modulate PKC delta interaction with mitochondria, resulting in neuronal cell death (36) . hnRNP K also has important roles in neuronal development and axonogenesis (38, 39) suggesting that changes to its metabolism could have significant outcomes in neurological disorders. Recently, additional hnRNP molecules, including hnRNP A1 and hnRNP A3 have been linked to ALS and FTLD (11, 13) . In the study by Mori et al, hnRNP A3 was found to interact with the hexanucleotide expanded repeat associated with C9orf72 and aggregated in the cytosol including in some patients with C9orf72 mutations (11) . These hnRNPs are known to be controlled by kinases including p38, ERK and JNK and it will be important to determine if these or alternative kinases control accumulation of the hnRNPs during ALS or FTLD. Interestingly, the study by Mori et al also found interaction between hnRNP K and the C9orf72 hexanucleotide repeat (GGGGCC) but this was not examined in detail. These studies do however, provide strong support for a common pathological process in ALS and FTLD involving cytosolic accumulation of hnRNPs. It remains to be determined if hnRNP K has a central role in any subset of these patients and if modulation of hnRNP K (and subsequently, TDP-43) can be achieved through pharmacological inhibition of key kinases. Materials and Methods Materials-4",6" Diamino-2-phenylindole dihydrochloride (DAPI) was obtained from Invitrogen (Mount Waverley, Victoria, Australia). N,N′-dimethyl-4,4′-bipyridinium dichloride (paraquat) and sodium arsenite, were from Sigma Aldrich (Sydney, NSW, Australia). Tocriscreen kinase inhibitor toolbox was from Tocris Bioscience (Ellisville, Melbourne, Victoria, Australia).
Polyclonal TDP-43 antisera were purchased from Proteintech Group (Chicago, IL, USA) to TDP-43 (10782-2-AP). Polyclonal antisera to total and phosphorylated hnRNP K, total hnRNP A1 and GFP were purchased from Abcam (Waterloo, Australia) and Enogene (Cherrybrook, NSW, Australia). Polyclonal antiserum to TIAR was from Cell Signaling Technology (Genesearch, Arundel, Queensland, Australia). Polyclonal antisera to CDK5 and p35, total and phospho-protein kinase C, total and phospho-p38 and total and phospho-CDK2 were from Santa Cruz Biotechnology (Scoresby, Victoria, Australia). Monoclonal antisera to HuR were obtained from Invitrogen (Mount Waverley, Victoria, Australia).
SH-SY5Y cell line-
Neuroblastoma SH-SY5Y cell line was passaged and maintained in DMEM/F12 plus 10% fetal bovine serum (FBS), 50units/ml penicillin and 50ug/ml streptomycin Cells were maintained in 5% CO 2 at 37 o C.
HEK 293 cell line-Human Embryonic Kidney 293 cells were maintained in DMEM media (25 mM glucose)
supplemented with 10% (v/v) FBS and penicillin/streptomycin and were maintained in 5% CO 2 at 37 o C. 
NSC34-TDP-43 cell line-

Western blot analysis of protein expression and phosphorylation-Cell lysates prepared in Phosphosafe
Extraction Buffer at equal protein concentration were mixed with electrophoresis SDS sample buffer and separated on 12% SDS-PAGE Tris-Glycine gels. Proteins were transferred to PVDF membranes and blocked with 4% skim milk solution in PBST before immunoblotting. Membranes were probed with polyclonal antisera against TDP-43 (1:5,000), total or phospho-hnRNP K, (1:1,000), total or phospho-CDK2
(1:1,000), CDK5 and p25/35 (1:1,000) or HuR (1:1,000). Secondary antiserum was rabbit-HRP at 1:5,000 dilution. Blots were developed using GE Healthcare ECL Advance Chemiluminescence (Rydalmere, NSW, Australia) and imaged on a Fujifilm LAS3000 imager (Berthold, Bundoora, Victoria, Australia). Expression of GAPDH was determined using antisera at 1:5,000 for protein loading controls where necessary.
Expression vectors and site directed mutagenesis-WT full-length hnRNP K GFP fusion construct cloned
into the pEGFP-C1 vector was used for site-directed mutagenesis of hnRNP K phosphorylation sites. To mutate serine CDK2 phosphorylation sites (Ser216 and Ser284) to alanine residues in hnRNP K, the GeneArt® Site-Directed Mutagenesis System (Life technologies) was employed according to the manufacturer's instructions. The mutagenic primer pairs used for Ser216Ala were 5' forward:
ATCCTTGACCTTATAGCTGAGCTCCCATCA and 3' reverse:
TGATGGGAGACTCAGCTATAAGGTCAAGGAT. The mutagenic primer pairs used for Ser284Ala were 5' forward: GATTATGATGATATGGCCCCTCGTCGAGGACC and 3' reverse:
GGTCCTCGACGAGGGGCCATATCATCATAATC. All mutants were verified by sequencing. Stress granules were determined as positive if they were distinctly brighter than the surrounding cytoplasmic or nuclear immunofluorescence and/or were clearly separated from surrounding immunofluorescence to allow positive identification of a discrete structure. Images shown are representative of multiple fields and replicate or triplicate coverslips per experiment (23) .
Immunoprecipitation-SH-SY5Y cell cytosolic fractions were prepared as previously described (43) and protein concentrations were determined by BCA protein assay (Pierce). Immunoprecipitations were carried out as previously described (43) neurons. Bar = 20 m. Expression of CDK2 was quantitated using Image J 1.46r software in nucleus. As a control, tissues from the same controls and cases were examined for expression of the general neuronal marker, neurofilament H (NF H). * P<0.05 compared to control, using one way ANOVA. 
